Document is current
Any future updates will be listed below
-
Authors
Jacob Berger, Adi
Gigi, Elinor
Kupershmidt, Lana
Meir, Zohar
Gavert, Nancy https://orcid.org/0000-0003-1639-4684
Zwang, Yaara
Prior, Amir
Gilad, Shlomit
Harush, Uzi
Haviv, Izhak
Stemmer, Salomon M.
Blum, Galia
Merquiol, Emmanuelle
Mardamshina, Mariya https://orcid.org/0000-0003-0066-0861
Kaminski Strauss, Sivan
Friedlander, Gilgi
Bar, Jair
Kamer, Iris
Reizel, Yitzhak
Geiger, Tamar
Pilpel, Yitzhak
Levin, Yishai
Tanay, Amos
Barzel, Baruch https://orcid.org/0000-0001-8862-4384
Reuveni, Hadas
Straussman, Ravid https://orcid.org/0000-0002-9476-329X
- License Information
-
More Information
Article History
Received: 13 March 2020
Accepted: 23 August 2021
First Online: 21 October 2021
Competing interests
: R.S. and N.G. serve as external consultants to CuResponse, a company that utilizes ex vivo organ culture technology and have been issued equity incentives in the company. H.R. and L.K. are employees of TyrNovo, a company that develops NT219 as a potential anticancer agent, are co-inventors on NT219 patent/patent applications and have been issued equity incentives in the company. I.H. and S.M.S. are consultants of TyrNovo and have been issued equity incentives in the company.
